中华放射医学与防护杂志
中華放射醫學與防護雜誌
중화방사의학여방호잡지
Chinese Journal of Radiological Medicine and Protection
2013年
3期
294-298
,共5页
小细胞肺癌%预防性全脑放射治疗%脑转移%健康相关生命质量%疗效
小細胞肺癌%預防性全腦放射治療%腦轉移%健康相關生命質量%療效
소세포폐암%예방성전뇌방사치료%뇌전이%건강상관생명질량%료효
Small cell lung cancer%Prophylactic cranial irradiation%Brain metastasis%Health related quality of life%Therapeutic efficacy
目的 分析小细胞肺癌患者行预防性全脑放射治疗(PCI)的生存率、脑转移发生率及健康相关生命质量.方法 分析2007年8月至2011年4月42例接受预防性全脑放射治疗的小细胞肺癌患者的临床资料,以Kaplan-Meier法计算生存率,采用非参数Wilcoxon test法比较PCI治疗前后患者的健康相关生命质量(HRQOL)评分.结果 42例患者PCI后的中位生存期为23个月(95% CI,15.05~30.95),中位无进展生存期为17个月(95% CI,14.33~19.67),PCI后的1年、2年和3年生存率分别为85.5%、45.8%和36.6%.全组患者行PCI后至发生脑转移的中位时间为15个月(95% CI,12.44~17.56),1年和2年的无脑转移发生率分别为77.6%和54.1%.健康相关生命质量分析,除认知功能(PCI后6周及6个月Z=-4.69、-3.36,P<0.05)外,PCI对其他功能影响较小,但出现一定症状的不良反应.结论 局限期小细胞肺癌放化疗后达到完全或接近完全缓解以及广泛期小细胞肺癌化疗有效的患者中进行PCI,可显著降低脑转移发生率,延长生存时间,且不良反应低,短期内对患者的总体生活质量未有明显影响.
目的 分析小細胞肺癌患者行預防性全腦放射治療(PCI)的生存率、腦轉移髮生率及健康相關生命質量.方法 分析2007年8月至2011年4月42例接受預防性全腦放射治療的小細胞肺癌患者的臨床資料,以Kaplan-Meier法計算生存率,採用非參數Wilcoxon test法比較PCI治療前後患者的健康相關生命質量(HRQOL)評分.結果 42例患者PCI後的中位生存期為23箇月(95% CI,15.05~30.95),中位無進展生存期為17箇月(95% CI,14.33~19.67),PCI後的1年、2年和3年生存率分彆為85.5%、45.8%和36.6%.全組患者行PCI後至髮生腦轉移的中位時間為15箇月(95% CI,12.44~17.56),1年和2年的無腦轉移髮生率分彆為77.6%和54.1%.健康相關生命質量分析,除認知功能(PCI後6週及6箇月Z=-4.69、-3.36,P<0.05)外,PCI對其他功能影響較小,但齣現一定癥狀的不良反應.結論 跼限期小細胞肺癌放化療後達到完全或接近完全緩解以及廣汎期小細胞肺癌化療有效的患者中進行PCI,可顯著降低腦轉移髮生率,延長生存時間,且不良反應低,短期內對患者的總體生活質量未有明顯影響.
목적 분석소세포폐암환자행예방성전뇌방사치료(PCI)적생존솔、뇌전이발생솔급건강상관생명질량.방법 분석2007년8월지2011년4월42례접수예방성전뇌방사치료적소세포폐암환자적림상자료,이Kaplan-Meier법계산생존솔,채용비삼수Wilcoxon test법비교PCI치료전후환자적건강상관생명질량(HRQOL)평분.결과 42례환자PCI후적중위생존기위23개월(95% CI,15.05~30.95),중위무진전생존기위17개월(95% CI,14.33~19.67),PCI후적1년、2년화3년생존솔분별위85.5%、45.8%화36.6%.전조환자행PCI후지발생뇌전이적중위시간위15개월(95% CI,12.44~17.56),1년화2년적무뇌전이발생솔분별위77.6%화54.1%.건강상관생명질량분석,제인지공능(PCI후6주급6개월Z=-4.69、-3.36,P<0.05)외,PCI대기타공능영향교소,단출현일정증상적불량반응.결론 국한기소세포폐암방화료후체도완전혹접근완전완해이급엄범기소세포폐암화료유효적환자중진행PCI,가현저강저뇌전이발생솔,연장생존시간,차불량반응저,단기내대환자적총체생활질량미유명현영향.
Objective To analyze the survival,brain metastases and health-related quality of life (HRQOL) for small cell lung cancer patients after prophylactic cranial irradiation(PCI).Methods From Aug 2007 to Apr 2011,42 small cell lung cancer patients were eligible for analysis.Overall survival rate was estimated by the Kaplan-Meier method.The HRQOL scores before and after PCI were compared by the nonparameter wilcoxon test.Results The median survival time from the start of PCI was 23 months(95% CI,15.05-30.95),progression free survival time was 17 months (95% CI,14.33-19.67),1-,2-and 3-year survival rates were 85.5%,45.8% and 36.6%,respectively.The median time from PCI to brain metastases was 15 months(95% CI,12.44-17.56),1-and 2-year brain metastases rates were 77.6% and 54.1%.PCI had a little influence on HRQOL scales except for cognitive function.Conclusions For patients with limited stage small cell lung cancer who achieve complete or nearly complete remission after initial treatment as well as patients with extensive stage who respond to initial chemotherapy,PCI is effective in decreasing the rate of brain metastasis and improving survival,while the adverse effects is acceptable.There is no significant impact on HRQOL scales during short term.